Abstract
He development of biological agents has provided rheumatologists with a variety of new and effective treatment options. The success of these agents in the treatment of rheumatoid arthritis, has spurred research into novel targets for the management of other rheumatic diseases. In addition to rheumatoid arthritis, TNF-α inhibitors (infliximab and / or etanercept) have been approved for the use in patients suffering from Crohns disease, ankylosing spondylitis and psoriatic arthritis. Also the treatment of persistent monoarticular and oligoarticular arthritis, resistant to disease modifying antirheumatic drugs and steroid therapies, with intra-articular anti-TNF therapy appears promising. Most importantly, such therapies have improved the quality of life and clinical outcomes in this group of patients. This article reviews the recent clinical studies published and ongoing research on the treatment of rheumatic diseases, other than rheumatoid arthritis, using these biological agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
